A survey of on platinum ineligible in head and neck cancer patients in India

Pawar, Dilip; Ahmed, Ramez; Chaudhari, Sameer

doi:10.1093/annonc/mdx676.019

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patient characteristics such as age, gender, comorbidities, and performance status influenced treatment decision‐making 54,57,71,76,80,89,94–100 . One study described gender bias in the treatment of osteosarcoma and the neglect of female patients 66 .…”

Section: Resultsmentioning

confidence: 99%

“…Patient characteristics such as age, gender, comorbidities, and performance status influenced treatment decision‐making. 54 , 57 , 71 , 76 , 80 , 89 , 94 , 95 , 96 , 97 , 98 , 99 , 100 One study described gender bias in the treatment of osteosarcoma and the neglect of female patients. 66 Other factors included treatment toxicities, 46 , 48 , 49 , 51 , 53 , 54 , 56 , 57 , 63 , 66 , 70 , 74 , 79 , 80 , 85 , 87 , 89 , 93 , 98 , 100 , 101 , 102 , 103 specific disease features, 50 , 51 , 56 , 57 , 59 , 64 , 76 , 77 , 80 , 96 , 98 , 104 the results of diagnostic workup, 65 ,…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Factors influencing treatment decision‐making for cancer patients in low‐ and middle‐income countries: A scoping review

et al. 2023

View full text Add to dashboard Cite

PurposeIn this scoping review, we evaluated existing literature related to factors influencing treatment decision‐making for patients diagnosed with cancer in low‐ and middle‐income countries, noting factors that influence decisions to pursue treatment with curative versus non‐curative intent. We identified an existing framework for adult cancer developed in a high‐income country (HIC) context and described similar and novel factors relevant to low‐and middle‐income country settings.MethodsWe used scoping review methodology to identify and synthesize existing literature on factors influencing decision‐making for pediatric and adult cancer in these settings. Articles were identified through an advanced Boolean search across six databases, inclusive of all article types from inception through July 2022.ResultsSeventy‐nine articles were identified from 22 countries across six regions, primarily reporting the experiences of lower‐middle and upper‐middle‐income countries. Included articles largely represented original research (54%), adult cancer populations (61%), and studied patients as the targeted population (51%). More than a quarter of articles focused exclusively on breast cancer (28%). Approximately 30% described factors that influenced decisions to choose between therapies with curative versus non‐curative intent. Of 56 reported factors, 22 novel factors were identified. Socioeconomic status, reimbursement policies/cost of treatment, and treatment and supportive care were the most commonly described factors.ConclusionsThis scoping review expanded upon previously described factors that influence cancer treatment decision‐making in HICs, broadening knowledge to include perspectives of low‐ and middle‐income countries. While global commonalities exist, certain variables influence treatment choices differently or uniquely in different settings. Treatment regimens should further be tailored to local environments with consideration of contextual factors and accessible resources that often impact decision‐making.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Factors influencing treatment decision‐making for cancer patients in low‐ and middle‐income countries: A scoping review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…24 Therefore, an early nutritional approach to patients with SCCHN can reduce weight loss and improve outcomes. 25 Weight loss in the 6 months prior to treatment does not appear to affect the development of late chemoradiotherapy-related toxicity. 23 However, pretreatment weight loss is associated with treatment failure, locoregional recurrence, distant metastases, and reduced overall survival (OS).…”

Section: Covid-19mentioning

confidence: 96%

“… 24 Therefore, an early nutritional approach to patients with SCCHN can reduce weight loss and improve outcomes. 25 …”

Section: Suitability For Cisplatin Chemotherapymentioning

confidence: 99%

Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice

Falco

Oliveira

Cacicedo

et al. 2021

CMAR

View full text Add to dashboard Cite

Cisplatin is the standard of treatment for squamous cell carcinoma of the head and neck (SCCHN) that has demonstrated efficacy, either in locally advanced disease when combined with radiotherapy at high doses, or in metastatic/recurrent disease when combined with other agents. However, the usual toxicities related to cisplatin, such as neurotoxicity, nephrotoxicity, ototoxicity, and hematologic toxicities, especially when high doses have been administered, have important implications in the patients’ quality of life. The decision to administer cisplatin depends on several patient factors, such as age, performance status, weight loss, comorbidities, previous toxicities, chronic viral infection, or even the current SARS-CoV-2 pandemic. In order to establish recommendations for the management of patients with SCCHN, a group of experts in medical and radiation oncology from Spain and Latin-American discussed how to identify patients who are not candidates for cisplatin to offer them the most suitable therapeutic alternative.

show abstract

A survey of on platinum ineligible in head and neck cancer patients in India

Cited by 2 publications

References 0 publications

Factors influencing treatment decision‐making for cancer patients in low‐ and middle‐income countries: A scoping review

Factors influencing treatment decision‐making for cancer patients in low‐ and middle‐income countries: A scoping review

Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice

Contact Info

Product

Resources

About